Forodesine Hydrochloride

Most primary testicular malignant lymphomas are derived from B-cell, with only a few cases of T-cell origin (primary testicular T cell lymphoma; PTTCL). In this report, we present a case of PTTCL who relapsed simultaneously in the central nervous system (CNS) and peripheral nerves, which was managed by allogeneic hematopoietic stem cell transplantation, but recurred again in the CNS. Treatment with the purine nucleotide phosphorylase inhibitor Forodesine achieved a therapeutic response. This finding suggests that Forodesine might be useful as a treatment option for CNS relapse in heavily treated T-cell lymphoma.

The stent-assisted coiling (SAC) and flow-diverter stent (FDS) techniques are widely used in the endovascular treatment of paraclinoid aneurysms. This article compares the occlusion rate, periprocedural complications, and clinical outcomes of SAC and FDSs.

Between January 2010 and December 2020, a systematic search of electronic databases identified 2283 articles for screening. After the application of inclusion and exclusion criteria, data were extracted for a meta-analysis of the proportions.

Of 23 articles containing 4 comparative studies, 27 cohorts were included, and 1208 patients with 1328 aneurysms were analyzed: In 10 cohorts, 381 (28.7%) patients were treated with SAC, whereas in 17 cohorts, 947 (71.3%) patients were treated with FDSs. In the comparative studies, no significance was observed between the 2 treatments. In the pooled cohorts, complete occlusion was achieved in 85% of aneurysms after treatment with FDSs (95% CI: 0.81–0.88, I2=34.7%) and 76% after treatment with SAC (95% CI: 0.70–0.81, I2=16.6%); the subgroup analysis was statistically significant (P=0.003). New visual complications were observed in 5% of the FDS-treated group (95% CI: 0.02–0.09, I2=76.9%) and in 1% of the SAC-treated group (95% CI: 0.00–0.02, I2=0%); the subgroup analysis was statistically significant (P=0.018). Other observational indices, including total procedure-related complications; hemorrhagic, thrombotic, and ischemic complications; permanent morbidities, and favorable neurological outcomes, showed no statistical significance between the groups.

Compared with SAC, treatment with FDSs may have a higher complete occlusion rate at follow-up. The similarly low rates for procedure-related complications and permanent morbidities indicate that both treatments are safe. A higher rate of new visual complications was noted in the FDS-treated group. Further research is required for direct comparisons along with a complete ophthalmological examination.